AI Article Synopsis
- Retinal vein occlusion (RVO) is a prevalent cause of vision loss, and while various treatments exist, there's a lack of standardized protocols and strong evidence for their effectiveness.
- This study explored the effects of traditional Chinese medicine Fufang XueShuan Tong (FXST) on RVO, using an induced model in rabbits divided into treatment and control groups to assess different dosages.
- Results showed that FXST treatment led to faster reopening of blood vessels, improved visual function, and changes in important biochemical markers, indicating its potential to aid in retinal recovery and inhibit harmful factors associated with RVO.
Article Abstract
Background: Retinal vein occlusion (RVO) is one of the most common causes of visual loss. Many approaches have been tried to treat central retinal vein occlusion (CRVO), and branch retinal vein occlusion (BRVO) with various results. However, there is no defined protocol and limited evidence to support the interventions currently used. The aim of this study was to assess the efficacy of the traditional Chinese medicine Fufang XueShuan Tong (FXST) in treating experimentally created RVO.
Methods: RVO model was first induced in forty-four pigmented rabbits through photocoagulation following injection of rose Bengal. The rabbits were divided into four groups based on the dose of FXST administered (212 mg/kg, 424 mg/kg, 848 mg/kg and control group). The rabbits were observed for four weeks after the procedure, using color fundus photography, fundus fluorescein angiography and electroretinogram examination. Vascular endothelial growth factor (VEGF), interleukin-6 and nitric oxide (NO) levels in the vitreous and histopathologic evaluation were monitored.
Results: The obstructed vessels in the treatment groups reopened or anastomosed faster than those in the control group (P < 0.05). The amplitude of maximum b wave and the oscillatory potential were significantly higher in the treatment groups than in the control group (P < 0.01). At both two weeks and four weeks, VEGF and IL-6 levels in the vitreous were significantly decreased in the treatment groups (P < 0.01), while NO levels were significantly elevated (P < 0.01). At the same time, histopathologic evaluation showed different retinal neuroepithelium structures in the different groups. Immunoreactivity of VEGF was greater in the control group than in the treatment groups.
Conclusion: FXST was helpful in reconstructing retinal vessels in the RVO model, protecting retinal structures and improving visual function, and could inhibit the neovascular factor.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Case report: Cilioretinal artery occlusion combined with central retinal vein occlusion as the initial presentation of pulmonary arterial hypertension.
Front Med (Lausanne)
December 2024
Department of Ophthalmology, Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.
Article Synopsis
- PAH can cause serious ocular conditions like CRVO and CilRAO due to high blood pressure in the lungs affecting blood flow to the eyes.
- A 13-year-old girl with a history of heart surgery experienced sudden vision loss, with tests revealing both CRVO and CilRAO, along with signs of severe PAH.
- Treatment with Bosentan and traditional Chinese medicine led to significant vision improvement, highlighting the importance of addressing cardiovascular issues to prevent eye complications and the need for a comprehensive approach in such complex cases.
Comparison of Renal Adverse Events Between Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Meta-Analysis.
Am J Ophthalmol
December 2024
Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Ontario, Canada; Department of Ophthalmology, St. Michael's Hospital/Unity Health Toronto, Toronto, Ontario, Canada. Electronic address:
Purpose: To assess the risk of renal adverse events, particularly acute kidney injury (AKI), between intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents.
Design: Meta-analysis.
Methods: A systematic literature search was conducted on Ovid Medline, Embase and the Cochrane Library for randomized controlled trials (RCTs) published from January 2005 to February 2024 involving adult patients receiving anti-VEGF intravitreal injections for agerelated macular degeneration, diabetic macular edema, and macular edema secondary to retinal vein occlusion.
Machine Learning Quantification of Fluid Volume in Eyes With Retinal Vein Occlusion Treated With Aflibercept: The REVOLT Study.
J Vitreoretin Dis
December 2024
Octane Imaging Lab, Toronto, ON, Canada.
Article Synopsis
- The study examined how ischemia, retinal fluid, and layer thickness impact visual acuity (VA) in patients with retinal vein occlusion (RVO) using swept-source optical coherence tomography (OCT).
- Patients received aflibercept injections and were monitored through OCT analysis at baseline and after 3 and 6 months, correlating OCT findings with changes in best-corrected VA (BCVA).
- Results showed that a combination of intraretinal fluid (IRF) volume, thickness measurements in specific retinal layers, and ischemic indices had the strongest correlation with changes in VA, highlighting useful clinical markers for RVO management.
Drug-induced retinal vein occlusion: a disproportionality analysis from the FDA adverse event reporting system (2004-2023).
Front Pharmacol
December 2024
Department of Ophthalmology, Hui'an County Hospital, Quanzhou, Fujian, China.
Introduction: Retinal vein occlusion (RVO) often causes irreversible visual impairment, making early prevention crucial. This study aims to identify associations between different medications and RVO and provide information for clinical practice.
Method: This study included reports of RVO from the FDA Adverse Event Reporting System (FAERS) database from the first quarter (Q1) of 2004 to the fourth quarter (Q4) of 2023.
Outliers of Treatment Frequency in Retinal Vein Occlusion: 24-Month Comparative Analysis of Fight Retinal Blindness! Practitioners.
Clin Exp Ophthalmol
December 2024
The Save Sight Institute, Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia.
Background: We aimed to describe a 2-year outcome of eyes managed by practitioners benchmarked using a funnel plot by their frequency of treatment using vascular endothelial growth factor (VEGF) inhibitors for naive retinal vein occlusion (RVO).
Methods: A multicentre, international, observational study of 29 doctors in 12 countries managing 1110 eyes with RVO commencing VEGF inhibitors between 1 January 2012-2022 tracked in the Fight Retinal Blindness! registry.
Results: We identified 3 outlying 'intensive' practitioners (managing 350/1110 eyes [32%]), 22 'typical' practitioners (604/1110, [54%]) and 4 outlying 'relaxed' practitioners (156/1110, [14%]) with respective 24-month outcomes in Branch and Central RVO including the primary outcome, mean adjusted change in visual acuity (VA) in BRVO: +16.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!